Core 1: Planning and Evaluation

核心1：规划与评估

基本信息

批准号：
10762163
负责人：
David K Ann
金额：
$ 12.42万
依托单位：
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-22 至 2028-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10762163
关键词：
Award California City of Hope Comprehensive Cancer Center Clinical Trials Collaborations Communities Comprehensive Cancer Center Contractor Databases Education Educational process of instructing Educational workshop Effectiveness Equity Evaluation Feedback Funding Future Goals Grant Individual Joints Knowledge Leadership Measures Mentors Mentorship Modeling Monitor Outcome Measure Performance Pilot Projects Play Process Program Evaluation Progress Reports Publications Recommendation Reporting Research Research Personnel Resources Structure Surveys Therapeutic Training Training Programs Training and Education Translational Research United States National Institutes of Health Universities Work anticancer research cancer health disparity career career development drug development equity, diversity, and inclusion health disparity improved insight meetings outreach programs success webinar

项目摘要

The goals of the Planning and Evaluation Core (PEC) are to monitor, evaluate, and assess the progress of our U54 Partnerships in meeting its milestones, objectives, and goals. The Core supports our University of California, Riverside (UCR) – City of Hope Comprehensive Cancer Center (CoHCCC) U54 Partnership’s goals of capacity- building, education, and training. Together in this U54, UCR and CoHCCC aim to develop the collaborations, translational resources, and training programs to enhance diversity in cancer research and achieve equity in drug development - throughout the entire drug development pipeline. To achieve our PEC’s goals we are guided by four boards – the Internal Advisory Board (IAB), External Advisory Board (EAB), Community Advisory Board (CAB), and Diversity, Equity, and Inclusion Board (DEI). Our IAB and EAB have served a key role in guiding our P20 planning grant; in our proposed U54 these two boards will be joined by our newly created CAB and DEI. The inclusion of these two new boards underscores our U54’s commitment to 1) serving the diverse individuals that live in our Southern California communities and 2) to mentor and train a diverse early-stage investigators who are committed to eliminating our current disparities in cancer therapeutics, drug development, and access to clinical trials. Through the activities and oversight of the PEC, our four advisory boards will 1) conduct evaluation, tracking, and reporting of the progress of projects and cores and 2) provide focused feedback to program U54 leadership and investigators. As in our P20 planning grant, the U54 PEC will work with the IAB to provide a structured and rigorous review process to select new Full and Pilot projects as well as Mini-Pilots for the Capacity Core. The PEC will assess all components of our U54 partnership. The PEC will assure that the 1) Research and Evaluation Core training and education programs are effective in providing education and building capacity, 2) Outreach Core works with investigators to be inclusive of the communities we serve, and 3) Capacity Core identifies provides early-stage investigators (ESI) with mentorship in target identification, drug development, and clinical trials. We anticipate that together our Cores will play a key role in developing future U54 projects that build UCR’s capacity in drug development and clinical trials.

计划和评估核心（PEC）的目标是监视，评估和评估我们的进度 U54会议的伙伴关系是里程碑，目标和目标。 Riverside（UCR） - 希望之城综合癌症中心（COHCCC）U54伙伴关系的目标目标 - 在U54中一起建造，教育和培训，旨在发展合作转化资源和培训计划，以增强癌症研究和成就的多样性药物开发 - 整个药物开发管道。由四个董事会 - 内部顾问委员会（IAB），外部咨询委员会（EAB），评论咨询委员会（CAB）以及多样性，公平和包容委员会（DEI）。 P20 Planning Grant在我们的支架U54中，这两个董事会将由我们新创建的CAB和DEI加入。包括两个新董事会的包含强调了我们对U54对1）服务的承诺。生活在我们南加州的南加州社区和2）Tomentor并培训一名多样化的早期调查员他们很努力消除我们目前在癌症治疗，药物开发和进入方面的差异通过临床试验。评估，跟踪和报告项目和核心的进度以及2）为重点反馈提供在我们的P20计划赠款中，U54的领导力和调查人员提供一个结构化和严格的审核过程，以选择新的完整和试点项目以及迷你行李 PEC的能力核心将评估我们U54合作伙伴的所有组成部分。 1）研究和评估核心培训和教育计划在普罗维登斯教育和建筑能力，2）与调查人员合作，包括我们所服务的社区，3） Capace Core核心识别提供了早期研究人员（ESI），以实现目标固化，药物的目标指导。开发和临床试验。 U54项目在药物开发和临床试验方面建立了UCR的Capace。